Correlation Between Plasma High Mobility Group Protein N1 Level and the Prognosis of Patients with Acute Cerebral Infarction: Preliminary Findings
Yufeng Lin,Kaiyuan Wang,Daowen Ji,Zhongying Gong,Zhiyun Wang
DOI: https://doi.org/10.2147/NDT.S359879
IF: 2.989
2022-04-21
Neuropsychiatric Disease and Treatment
Abstract:Yufeng Lin, 1 Kaiyuan Wang, 2 Daowen Ji, 1 Zhongying Gong, 1 Zhiyun Wang 1 1 Department of Neurology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, People's Republic of China; 2 Department of Anesthesiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China Correspondence: Zhiyun Wang; Zhongying Gong, Department of Neurology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, 300192, People's Republic of China, Tel +86 22-23626600, Fax +86 22-23626600, Email ; Purpose: To investigate the correlation between plasma levels of high mobility group protein N1 (HMGN1) and the severity of neurological deficits and prognosis in patients with acute cerebral infarction (ACI). Patients and Methods: The plasma HMGN1 levels of 108 patients with ACI were detected by ELISA. The National Institutes of Health Stroke Scale (NIHSS) and the modified Rankin Scale (mRS) were used to assess the neurological impairment and outcomes of these patients, respectively. The correlation between HMGN1 levels and clinical parameters was analyzed. Results: The plasma HMGN1 levels of patients with ACI were positively correlated with their NIHSS and mRS scores. Patients with the large artery atherosclerosis (LAA) subtype in the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification had higher plasma HMGN1 levels than patients with other subtypes. Conclusion: HMGN1 levels are positively correlated with the severity of ACI and could be used to predict the prognosis of these patients. HMGN1 can be used as a biological marker and potential target for clinical assessment and therapy of ACI. Keywords: high mobility group protein N1, alarmins, cerebral infarction, neurologic examination Acute cerebral infarction (ACI) is the most common type of stroke, accounting for 69.6–70.8% of all stroke cases. 1 ACI causes neurological deficits and even death due to different degrees of neuronal ischemia and necrosis, which poses a great risk to human health. Studies have shown that a series of inflammatory responses occur in the brain after ACI and that the imbalance in the secretion of cellular inflammatory factors can further promote the occurrence and development of cerebral infarction. 2 Alarmins are a class of endogenous mediators that are rapidly released extracellularly when the body is stimulated by danger signals; they further activate the natural immune system. 3,4 The high-mobility group (HMG) proteins consist of three families, HMGA, HMGB, and HMGN. 5,6 HMGB1 and HMGN1 have been shown to function as alarmins. 4,7 HMGB1 is a highly abundant intracellular non-histone chromosome-binding protein that is expressed in various tumor tissues and is involved in tumor invasion and metastasis; 8 it is reported to correlate with the severity of acute cerebral infarction. 9 HMGN1 is a highly conserved non-histone protein that regulates gene expression and affects chromosome structure by acting directly on nucleosomes in the nucleus, thus participating in various critical biological processes. 10 Studies have demonstrated that the plasma HMGN1 level is associated with metastasis and the prognosis of patients with non-small cell lung cancer (NSCLC), 11 while there are no studies on the relationship between HMGN1 and the progression of ACI. In this study, we investigated the correlation between plasma HMGN1 levels and the National Institutes of Health Stroke Scale (NIHSS) and the 3-month modified Rankin Scale (mRS) in ACI patients, providing theoretical support for the further assessment and treatment of ACI. One hundred eight patients with ACI who were hospitalized in the Department of Neurology of Tianjin First Central Hospital from March 2019 to March 2021 were enrolled, with 56 men and 52 women aged 38 to 75 years. The clinical manifestations and head CT and/or MRI findings met the diagnostic criteria for ACI. There were 42 cases of basal nucleus infarction, 18 cases of thalamic infarction, 25 cases of lobar infarction, 12 cases of cerebellar infarction, and 11 cases of brainstem infarction. According to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification, there were 35 cases of small artery occlusions (SAO), 30 cases of large artery atherosclerosis (LAA), 20 cases of cardioembolism (CE), 11 cases of stroke of other determined etiologies (SOE), and 12 cases of stroke of undetermined etiology (SUE). The inclusion criteria were as follows: (1) acute onset, admitted within 72 hours of symptoms onset; (2) focal neurological deficits (weakness or numbness of one side of the face or limb, l -Abstract Truncated-
psychiatry,clinical neurology